Why Hepatologists Get Sued: Missed HCC Surveillance, Drug-Induced Liver Injury, and Transplant-Listing Delays

By John Mahoney · July 2026 · 8 min read

Hepatology is a small, high-acuity internal-medicine subspecialty, and its malpractice profile reflects that: relatively few claims, but the ones that arise tend to be catastrophic — a curable liver cancer that became terminal, a decompensation that ended in death, a transplant candidate who was never listed. Because hepatologists share patients with gastroenterologists, transplant surgeons, oncologists, and primary care, they are frequently named alongside those specialties, and a careful screen has to ask who actually owned the decision at issue.

This guide is for plaintiff-side medical-malpractice attorneys evaluating hepatology matters. It walks through the allegation profile, the cannot-miss scenarios that drive these claims, the contributing factors that turn a bad outcome into a payout, and what separates a strong liver-disease case from a weak one — with the caution that hepatology-specific closed-claim data is thin and much of the pattern below is inferred from gastroenterology and general internal-medicine analogues.

Disclaimer: This article is for informational purposes only and does not constitute legal advice. Hepatology claim data is limited and partly inferred from related specialties; the patterns here are directional and should be independently verified against the record before use in any matter.

The Allegation Profile

Liver-disease claims cluster in a few recognizable buckets, weighted heavily toward diagnostic and management failures rather than procedural error:

• Delayed or missed diagnosis of hepatocellular carcinoma (HCC). This is the signature hepatology claim. Guidelines call for HCC surveillance — typically imaging at regular intervals — in patients with cirrhosis or chronic hepatitis B, and the case is often that surveillance was never ordered, lapsed, or the abnormal result was not acted on.
• Failure to manage chronic liver disease and its complications — cirrhosis, portal hypertension, ascites, hepatic encephalopathy — leading to a preventable decompensation.
• Drug-induced liver injury (DILI) and medication management — hepatotoxic agents continued despite rising transaminases, acetaminophen exposure in a compromised liver, failure to dose-adjust for hepatic impairment.
• Failure to diagnose or work up abnormal liver chemistries — persistently elevated LFTs that were never worked up, a rising alpha-fetoprotein that sat, viral hepatitis that was never treated.
• Transplant-evaluation and listing failures — a decompensating candidate who was not referred, evaluated, or listed in time, or whose MELD-driven priority was mismanaged.
• Procedural complications — liver-biopsy bleeding, paracentesis injury, or complications of variceal banding.

The Cannot-Miss Scenarios

A handful of fact patterns recur and should elevate merit and exposure on intake:

• The lapsed HCC surveillance in a known cirrhotic. A patient with documented cirrhosis or chronic hepatitis B who should have been under a surveillance protocol, where the imaging was never ordered or the interval quietly stretched from months to years, and the cancer that would have been curable at an early stage was found late. This is the highest-value hepatology pattern because the standard is concrete and the causation story — earlier detection meant a curable tumor — is often clean.
• The abnormal imaging or AFP that returned and sat. A surveillance ultrasound that flagged a lesion, or a rising alpha-fetoprotein, where the closed-loop failed — the result came back and no follow-up imaging, biopsy, or referral followed.
• Untreated or mismanaged decompensation. Escalating ascites, encephalopathy, or a variceal bleed where the available intervention was deferred, ending in death or the loss of a transplant window.
• Drug-induced liver injury. A hepatotoxic medication continued in the face of climbing transaminases, or a dangerous interaction in a patient with reduced hepatic reserve.
• The transplant-listing gap. A candidate who met criteria but was never referred or listed, where the delay closed the window.

The single highest-value pattern is the missed HCC in a patient who was supposed to be under surveillance. It combines a concrete standard, a closed-loop failure, and a causation story that survives scrutiny — the three things that make a liver case strong.

The Contributing Factors That Drive Payouts

Bad outcomes in sick liver patients are common; what converts a bad outcome into a payable claim is usually one of these:

• Failure to order, track, or act on surveillance and lab results. In a specialty this lab- and imaging-driven, the defining systemic failure is the closed loop that never closed — the surveillance interval that lapsed, the AFP that returned unaddressed, the abnormal LFT that was never worked up.
• Communication failures. Handoffs between primary care, gastroenterology, hepatology, and the transplant center are a recurring fault line — the referral that was never made, the result that was never relayed, the consent that was never documented.
• Clinical-judgment and workup gaps. An inadequate evaluation of abnormal liver chemistries, a differential that never included HCC or DILI.
• Documentation gaps. Missing surveillance orders, absent evidence that a listing evaluation was considered, informed-consent gaps on biopsy or banding.

The defining hepatology question is whether the surveillance loop was closed and whether the abnormal result was acted on. A documented surveillance protocol with results tracked and escalated is a strong defense; a cirrhotic who fell out of surveillance and developed an advanced cancer is the plaintiff's case.

What Separates a Strong Case From a Weak One

The strong plaintiff case

• A patient with a documented indication for HCC surveillance who fell out of it — or an abnormal surveillance result that returned and was never acted on.
• A delay that converted a curable, early-stage cancer into an advanced or terminal one, with the hepatologist demonstrably owning the surveillance decision.
• A clean causation story: earlier detection would have changed the outcome, and the deferred intervention — not the underlying disease — drove the loss.
• A drug-induced-liver-injury or decompensation claim where a recognized, available intervention was deferred despite a clear warning in the labs.

The strong defense case

• A documented surveillance protocol with results tracked, escalated, and acted on — the right calls were made and the chart shows it.
• The co-defendant defense: the surveillance or listing decision belonged to primary care or the transplant center, and the hepatologist was named reflexively.
• Causation: the end-stage cirrhosis and comorbidity, not the timing, drove the death — a frequent and strong defense given how sick these patients are.

The weak case on either side ignores who owned the surveillance decision and what the results showed. A plaintiff theory that treats a catastrophic outcome in an end-stage liver patient as automatic negligence, or that names the hepatologist for a failure that belonged to primary care, will struggle on both attribution and causation. A defense that leans on comorbidity while a surveillance interval lapsed and an early cancer went undetected will not hold. And because the underlying data is thin, both sides should anchor on the contemporaneous record rather than on specialty-wide statistics.

Bottom Line

Hepatology is low-frequency and high-severity, and its defining claim is the missed HCC in a cirrhotic who should have been under surveillance — followed by drug-induced liver injury, mismanaged decompensation, and transplant-listing delays. These cases turn on whether the surveillance loop was closed, whether the abnormal result was acted on, whether the hepatologist actually owned the decision, and whether earlier action would have changed the outcome. Screen for the lapsed surveillance and the unaddressed abnormal lab, scrutinize attribution and causation early, and build the timeline from the record itself.

For how damages exposure varies across jurisdictions, see our medical malpractice damages-by-state tool, and if a pre-suit expert filing is required, run the certificate of merit readiness checker before drafting.

Questions? Contact us at [email protected] or (856) 979-6525

🔎 Screening a case in a different specialty? Browse all specialty malpractice-risk guides in one place — Why Doctors Get Sued: Malpractice Risk by Specialty →